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medical claims records for continuously enrolled adult (≥18 years) ﬁrst-time statin 
users. Patients were followed for one year. Liver enzyme and CK tests were identiﬁed 
using CPT-4 procedure codes. Descriptive statistics were used to characterize the 
population and estimate unadjusted associations between laboratory monitoring and 
patient characteristics. Multivariable logistic regression was used to estimate the odds 
of monitoring, controlling for age, gender, number of prescription drugs during statin 
use, diabetes, statin intensity, prescribing physician specialty, geographic region and 
health plan type. RESULTS: Between July 1, 1997 and March 31, 2007, there were 
66,228 new statin users in the study population. 14% of new users were given a liver 
enzyme test at baseline and 25% received follow-up tests. 3% of new users were given 
baseline CK tests. Odds of compliant baseline and follow-up liver enzyme testing were 
higher for those with previous liver disease (OR = 3.0, P < 0.0001) and diabetes (OR 
= 1.2, P < 0.0001). Cardiologists were less likely to order liver tests than family or 
general practitioners (OR = 0.68, P < 0.0001). It was estimated that about 19,000 
patients were indicated for a baseline CK test, based on risk factors, but only 2.6% 
of those patients received one. The odds of receiving compliant baseline CK tests 
increased for patients receiving high potency statins (OR = 1.7, P < 0.01). Cardiologists 
were more likely to order CK tests than family or general practitioners (OR = 1.8, P 
< 0.001). CONCLUSIONS: While rates of laboratory testing were low, adjusted odds 
suggest that patients at higher risk for adverse outcomes are more likely to receive 
compliant liver enzyme and CK monitoring.
PCV42
INPATIENT MORTALITY AND HOSPITALIZATION COSTS IN ATRIAL 
FIBRILLATION PATIENTS
Emons MF1, Lin J2, Yu HT1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Sanoﬁ-Aventis, Bridgewater, NJ, USA
OBJECTIVES: Although atrial ﬁbrillation/ﬂutter (AF) is a risk factor for cardiovas-
cular (CV) disease, its morbidity/mortality burden is uncertain. This retrospective 
cohort study examined CV hospitalization/mortality rates and associated costs among 
AF patients in the real-world setting. METHODS: The US MarketScan® database 
was used to identify adults with AF (≥1 AF hospital discharge or ≥2 non-diagnostic 
outpatient AF claims) and ≥18 months’ continuous enrollment data [≥12 months and 
≥6 months’ immediately before and after the ﬁrst qualifying (index) AF diagnosis] 
between January 2003 and September 2007. AF was classiﬁed as newly-diagnosed 
(ND) or pre-existing (PRE) based on AF diagnoses in the ﬁrst 12 months. CV hospi-
talization and mortality were assessed post-index diagnosis during a mean follow-up 
period of 20 months.RESULTS: Of 184,155 AF patients identiﬁed (mean 73 years, 
55% men), 119,486 had PRE and 64,669 had ND disease; common comorbidities 
included hypertension (60%), heart failure (31%), and diabetes (23%). During post-
index follow-up, 80,523 PRE patients (67%) vs. 51,240 ND patients (79%) were 
hospitalized. Admissions for CV causes were similarly frequent in patients with PRE 
and ND disease (mean 0.30 vs. 0.33 events/patient, respectively) and incurred similar 
costs per event for the two groups (mean US$11,898 vs. $12,257, respectively). Causes 
of CV admission (by DRG) in the overall cohort included cardiac arrhythmia (23%), 
myocardial infarction (3.8%), syncope (3.2%) and ‘other/unspeciﬁed’ (66%). Admis-
sions with an AF diagnosis were more frequent among patients with ND than PRE 
disease (mean 0.99 vs 0.61 events/patient), but hospital costs for the two groups were 
similar (mean US$12,059 vs. $11,984, respectively). In total, 2990 (2.5%) PRE 
patients and 1409 (2.2%) ND patients died in hospital, with most deaths occurring 
during admission with an AF diagnosis (58% in both groups). CONCLUSIONS: AF 
is accompanied by a high level of CV hospitalization with associated cost burden and 
mortality.
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OBJECTIVES: Approximately 140,000 percutaneous coronary interventions (PCIs) 
will be performed in France in 2009/2010. PCI complications often increase resource 
utilization. New antithrombotic therapies have the potential to improve outcomes and 
decrease costs. The ACUITY trial demonstrated a decreased mortality and a statisti-
cally signiﬁcant reduction in bleeding events with bivalirudin as compared to a 
heparin-plus-GPI (HEP+GPI) regimen. This analysis evaluated the economic impact 
of this improvement in the French hospital setting with a focus on reduced access 
site- and non-access site-related bleeding events. METHODS: A budget-impact model 
was developed to evaluate the impact of bivalirudin in high-risk (per ESC deﬁnition) 
UA/NSTEMI patients undergoing PCI in a French hospital. Clinical data for the model 
were derived from the ACUITY trial and included 30-day event rates for major com-
plications (total and non-access site bleeding, Q-wave myocardial infarction, repeat 
PCI and coronary artery bypass graft). Economic data were derived from French 
medical literature, including clinical event costs, ward costs (both regular and ICU/
CCU) and pharmaceutical costs. RESULTS: In 100 PCI patients, bivalirudin use would 
result in 4 fewer protocol-deﬁned major bleeding events (3.8%) and 12 fewer minor 
bleeding events (12.2%). Considering non-access site bleeding events only (all bleeds 
excluding retroperitoneal and access site bleeds), bivalirudin use would reduce major 
and minor bleeding events by 0.7% and 4.7%, respectively. Including all bleeding 
events, the total hospital budget impact of treating 100 high risk UA/NSTEMI patients 
using a HEP+GPI-based strategy is 3626,903. Introducing a bivalirudin-based strategy 
could save 332,520 (5%). The reduction in non-access site bleeding events alone could 
result in savings of 318,028 (3%) per 100 patients. CONCLUSIONS: A bivalirudin-
based strategy for anticoagulant use in high risk UA/NSTEMI patients undergoing PCI 
is associated with favorable clinical and economic outcomes when compared with 
HEP+GPI in a French hospital setting.
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OBJECTIVES: New antithrombotic therapies have the potential to improve clinical 
outcomes and decrease costs. The HORIZONS-AMI study of bivalirudin demon-
strated signiﬁcantly reduced clinical event rates (mortality and bleeding) compared to 
a heparin and glycoprotein IIa/IIIb inhibitor (HEP + GPI) regimen. Approximately 
24,000 PPCIs were performed in Italy in 2008, based on statistics published by GISE. 
The potential clinical and economic value of implementing a bivalirudin-based strategy 
for STEMI patients receiving PPCI is compared to current HEP + GPI-based practice, 
from a typical Italian hospital perspective. METHODS: A budget impact model was 
developed to compare treatment of STEMI patients undergoing PPCI with either 
bivalirudin or HEP + GPI. Clinical data for the model was derived from the HORI-
ZONS-AMI trial, and included 30-day event rates for major complications (protocol 
bleeding, Q-wave myocardial infarction, repeat PCI and coronary artery bypass graft 
procedures). Italian cost and clinical practice data were derived from published 
sources. RESULTS: Overall average procedure costs per HEP + GPI-treated patient 
were 37121. Treating patients with bivalirudin (incorporating 7.2% provisional GPI 
use per HORIZONS-AMI) saved 3529 per patient. In extrapolating these beneﬁts to 
a typical Italian hospital conducting 200 PPCI procedures per year: 2 deaths (1%); 8 
major bleeding events (3.7%); and 14 minor bleeding events (6.8%) could be averted 
if treated with bivalirudin. In addition, introducing a bivalirudin-based strategy to 
treat a typical cohort of 200 STEMI patients would save the hospital budget 3105,807 
(7%) per year. Extrapolating these savings to the total number of PPCI procedures 
performed in Italy in 2008 would result in savings of 31,270,000 in hospital expen-
ditures nationally. CONCLUSIONS: Using a bivalirudin-based strategy in STEMI 
patients undergoing PPCI is associated with favorable clinical and economic outcomes 
when compared with HEP + GPI in an Italian hospital setting.
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OBJECTIVES: Primary percutaneous coronary intervention (PPCI) has become the 
preferred treatment option for acute ST-segment elevation myocardial infarction 
(STEMI). In 2006, nearly 38,000 PPCI procedures were performed in Germany. New 
antithrombotic therapies have the potential to improve clinical outcomes and decrease 
costs. The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event 
rates (mortality and bleeding) compared to a heparin and GPI (HEP + GPI) regimen. 
The potential economic value of implementing bivalirudin in the PPCI setting is evalu-
ated in this analysis from a German hospital perspective. METHODS: A budget 
impact model was developed to compare treatment of STEMI patients undergoing 
PPCI with either bivalirudin or HEP + GPI. Clinical data for the model were derived 
from the HORIZONS trial database, and included 30-day event rates for major 
complications (bleeding as deﬁned by trial protocol, Q-wave myocardial infarction, 
and repeat PCI and coronary artery bypass graft procedures) and patient death. 
German cost and clinical practice data were derived from published sources, the 
German subset of the HORIZONS trial (n = 786) and the ADONIS registry. 
RESULTS: Overall average procedure cost per bivalirudin-treated patient (incorporat-
ing 7.2% provisional GPI use as per HORIZONS) was 38165, compared with 38,84 
per HEP + GPI-treated patient. In extrapolating these beneﬁts to a typical German 
hospital of 200 PPCI patients per year, 2 deaths (1%), 8 major bleeding events (3.7%), 
and 14 minor bleeding events (6.8%) in patients would be averted if treated with 
bivalirudin. The total hospital budget impact of treating 200 PPCI patients using a 
HEP + GPI based strategy is 31,770,814. Introducing a bivalirudin-based strategy 
could save 3137,817 (8%) per year. CONCLUSIONS: Using a bivalirudin-based 
strategy in STEMI patients undergoing PPCI is associated with favorable clinical and 
economic outcomes when compared with HEP + GPI in a German hospital setting.
